Showing 3721-3730 of 9301 results for "".
- AAD, Janssen, and Kenvue Mentor Next Generation of Dermatologistshttps://practicaldermatology.com/news/aad-janssen-and-kenvue-mentor-next-generation-of-dermatologists/2461884/As part of Pathways: Inclusivity in Dermatology, the American Academy of Dermatology (AAD), Janssen, and Kenvue sent high school and college students from diverse communities on a five-day experience in Washington, D.C. to learn about the dermatology field, get tips on how to successfully apply to…
- MRA Announces 2023 Dermatology Fellowship Award Recipientshttps://practicaldermatology.com/news/mra-announces-2023-dermatology-fellowship-award-recipients/2461878/The Melanoma Research Alliance (MRA) has announced its 2023 Dermatology Fellowship Award recipients. The awardees will each receive a $50,000 grant to support an independent research project focused on advancing melanoma prevention or detection. Along with critical financial support, the fellows …
- Almirall on Track for Net-Zero GHG emissions by 2050https://practicaldermatology.com/news/almirall-on-track-for-net-zero-ghg-emissions-by-2050/2461877/The Science-Based Targets initiative (SBTi) has validated Almirall’s Environmental, Social and Governance (ESG) targets to achieve net zero greenhouse gas (GHG) emissions across the value chain by 2050, under the 'Net-Zero Standard'. The company has also committed to reducing absolute GHG emission…
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technology combines reflectance co…
- Hoth Therapeutics Receives Protocol Approval for HT-001https://practicaldermatology.com/news/hoth-therapeutics-receives-protocol-approval-for-ht-001/2461873/Hoth Therapeutics, Inc. received approval from the Food & Drug Administration (FDA) for a protocol change in its Phase 2a clinical trial of HT-001. Participants will apply HT-001 Gel once per day for six weeks, during which the effect on treating acneiform rash and other skin disorders induced by…
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in order to give dermatol…
- News You Can Use: GW, Pfizer Offering Grants to Improve Access to Teledermatology in Underserved Areashttps://practicaldermatology.com/news/news-you-can-use-gw-pfizer-offering-grants-to-improve-access-to-teledermatology-in-underserved-areas/2461865/The George Washington University (GW) School of Medicine and Health Sciences (SMHS) and Pfizer Global Medical Grants are collaborating to offer a grant opportunity focused on broad implementation of GW’s Teledermatology Help Desk Clinic model in underserved areas across the United States. The prog…
- DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its Melanoma Testhttps://practicaldermatology.com/news/dermtech-adds-approximately-7-million-covered-lives-for-the-foundational-assay-of-its-melanoma-test/2461861/DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, West…
- RVL Launches New Prescription E-commerce Platformhttps://practicaldermatology.com/news/rvl-launches-new-prescription-e-commerce-platform/2461844/RVL Pharmaceuticals is launching a prescription e-commerce platform. ELEVATE is a secure subscription platform that allows both providers and patients to purchase RVL products. The platform comprises RVL-initiated auto refills and unlocks additional savings for practices, the Company states. RV…
- Nemolizumab Monotherapy Curbs Itch in Prurigo Nodularis by Week 4https://practicaldermatology.com/news/nemolizumab-monotherapy-curbs-itch-in-prurigo-nodularis-by-week-4/2461840/Nemolizumab monotherapy quickly tames itch in Prurigo Nodularis, according to a late-breaking late-breaking Phase III study presented at the 25th World Congress of Dermatology (WCD) in Singapore. Fully 19.7% of patients treated with nemolizumab monotherapy achieved an itch-free state as early as w…